The Relationship and Clinical Significance of Lactylation Modification in Digestive System Tumors
Overview
Affiliations
Lactylation, an emerging post-translational modification, plays a pivotal role in the initiation and progression of digestive system tumors. This study presents a comprehensive review of lactylation in digestive system tumors, underscoring its critical involvement in tumor development and progression. By focusing on metabolic reprogramming, modulation of the tumor microenvironment, and the molecular mechanisms regulating tumor progression, the potential of targeting lactylation as a therapeutic strategy is highlighted. The research reveals that lactylation participates in gene expression regulation and cell signaling by affecting the post-translational states of histones and non-histone proteins, thereby influencing metabolic pathways and immune evasion mechanisms in tumor cells. Furthermore, this study assesses the feasibility of lactylation as a therapeutic target, providing insights for clinical treatment of gastrointestinal cancers. Future research should concentrate on elucidating the mechanisms of lactylation, developing efficient lactylation inhibitors, and validating their therapeutic efficacy in clinical trials, which could transform current cancer treatment and immunotherapy approaches. In summary, this review emphasizes the crucial role of lactylation in tumorigenesis and progression through a detailed analysis of its molecular mechanisms and clinical significance.
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies.
Lv M, Huang Y, Chen Y, Ding K Exp Hematol Oncol. 2025; 14(1):32.
PMID: 40057816 PMC: 11889934. DOI: 10.1186/s40164-025-00622-x.
Lactate and lactylation in cancer.
Chen J, Huang Z, Chen Y, Tian H, Chai P, Shen Y Signal Transduct Target Ther. 2025; 10(1):38.
PMID: 39934144 PMC: 11814237. DOI: 10.1038/s41392-024-02082-x.
Lactate and lactylation in gastrointestinal cancer: Current progress and perspectives (Review).
He Y, Huang Y, Peng P, Yan Q, Ran L Oncol Rep. 2024; 53(1).
PMID: 39513579 PMC: 11574708. DOI: 10.3892/or.2024.8839.